Application | Comment | Organism |
---|---|---|
medicine | argatroban enhances fibrinolysis via a differential inhibition of thrombin-mediated activation of TAFI and factor XIII | Homo sapiens |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
additional information | argatroban enhances fibrinolysis via a differential inhibition of thrombin-mediated activation of TAFI and factor XIII: Plasma is exposed to argatroban or heparin, with coagulation initiated with kaolin/tissue factor and fibrinolysis initiated with tissue plasminogen activator. Argatroban significantly decreases clot lysis time and increases the maximum rate of lysis compared with unexposed plasma, whereas heparin exposure only diminishs clot lysis time. Experiments with TAFI-deficient and factor XIII-deficient plasma demonstrate a sparing of thrombin-mediated factor XIII activation with concurrent inhibition of TAFI activation | Homo sapiens |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | - |
- |
- |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
plasma | - |
Homo sapiens | - |
Synonyms | Comment | Organism |
---|---|---|
TAFI | - |
Homo sapiens |
thrombin-activatable fibrinolysis inhibitor | - |
Homo sapiens |